Technical Analysis for RETA - Reata Pharmaceuticals, Inc. - Class A

Grade Last Price % Change Price Change
grade B 86.59 1.68% 1.43
RETA closed up 1.68 percent on Friday, September 13, 2019, on 1.18 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical RETA trend table...

Date Alert Name Type % Chg
Spinning Top Other 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Walk Strength 1.68%
Overbought Stochastic Strength 1.68%
NR7 Range Contraction -2.65%
Doji - Bearish? Reversal -2.65%
Upper Bollinger Band Walk Strength -2.65%
Multiple of Ten Bearish Other -2.65%
Overbought Stochastic Strength -2.65%

Older signals for RETA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various serious or life-threatening diseases. The company focuses on drugs with novel mechanisms of action that modulate regulatory proteins called transcription factors. Its lead product candidates include bardoxolone methyl and RTA 408, which are members of a class of small molecules called antioxidant inflammation modulators. It is involved in LARIAT, a Phase II study of bardoxolone methyl for the treatment of pulmonary arterial hypertension and pulmonary hypertension due to interstitial lung disease. RTA 408 is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia and mitochondrial myopathies. Reata Pharmaceuticals, Inc. was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. The company was founded in 2002 and is headquartered in Irving, Texas.
Medicine Diseases Inflammation Health Care Pulmonary Arterial Hypertension Pulmonary Hypertension Myopathy Friedreich's Ataxia Interstitial Lung Disease
Is RETA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 104.53
52 Week Low 47.5
Average Volume 205,103
200-Day Moving Average 81.413
50-Day Moving Average 83.1896
20-Day Moving Average 79.234
10-Day Moving Average 83.764
Average True Range 4.015
ADX 27.41
+DI 23.2916
-DI 19.6737
Chandelier Exit (Long, 3 ATRs ) 78.205
Chandelier Exit (Short, 3 ATRs ) 82.045
Upper Bollinger Band 91.1975
Lower Bollinger Band 67.2705
Percent B (%b) 0.81
BandWidth 30.197895
MACD Line 1.6118
MACD Signal Line 0.0312
MACD Histogram 1.5806
Fundamentals Value
Market Cap 2.26 Billion
Num Shares 26.1 Million
EPS -1.06
Price-to-Earnings (P/E) Ratio -81.69
Price-to-Sales 15.55
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 91.99
Resistance 3 (R3) 91.75 89.72 91.09
Resistance 2 (R2) 89.72 88.34 89.84 90.79
Resistance 1 (R1) 88.15 87.49 88.94 88.39 90.49
Pivot Point 86.12 86.12 86.51 86.24 86.12
Support 1 (S1) 84.55 84.74 85.34 84.79 82.69
Support 2 (S2) 82.52 83.89 82.64 82.39
Support 3 (S3) 80.95 82.52 82.09
Support 4 (S4) 81.19